SPRO Spero Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Spero Therapeutics Inc reported revenue of $0 (down 100.0% from a year earlier), net income of −$9.55M and diluted EPS of −$0.16; over the last four quarters revenue was $47.0M and net income $7.38M; for the fiscal year ended December 2025 revenue was $66.8M, up 39.2% on the year before.
SPRO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $66.8M, gross profit n/a, operating income $6.31M, net income $8.57M (margin 12.8%), EPS $0.15
- Fiscal year ended Dec 2024: revenue $48.0M, gross profit n/a, operating income −$73.4M, net income −$68.6M (margin -142.9%), EPS −$1.27
- Fiscal year ended Dec 2023: revenue $104M, gross profit n/a, operating income $21.5M, net income $22.8M (margin 22.0%), EPS $0.43
- Fiscal year ended Dec 2022: revenue $53.5M, gross profit n/a, operating income −$42.2M, net income −$46.4M (margin -86.7%), EPS −$1.23
- Fiscal year ended Dec 2021: revenue $18.3M, gross profit n/a, operating income −$88.0M, net income −$89.8M (margin -491.9%), EPS −$2.91
SPRO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$9.55M, EPS −$0.16
- Quarter ended Mar 31, 2026: revenue $258K (down 95.6% year over year), net income −$7.20M, EPS −$0.13
- Quarter ended Dec 31, 2025 (from the annual report): revenue $41.3M (up 174.5% year over year), net income $31.5M, EPS $0.56
- Quarter ended Sep 30, 2025: revenue $5.44M (down 59.6% year over year), net income −$7.38M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue $14.2M (up 39.1% year over year), net income −$1.70M, EPS −$0.03
- Quarter ended Mar 31, 2025: revenue $5.87M (down 36.6% year over year), net income −$13.9M, EPS −$0.25
- Quarter ended Dec 31, 2024 (from the annual report): revenue $15.0M (down 79.5% year over year), net income −$20.9M, EPS −$0.38
- Quarter ended Sep 30, 2024: revenue $13.5M (down 47.1% year over year), net income −$17.1M, EPS −$0.32
- Quarter ended Jun 30, 2024: revenue $10.2M (up 275.4% year over year), net income −$17.9M, EPS −$0.33
- Quarter ended Mar 31, 2024: revenue $9.27M (up 347.9% year over year), net income −$12.7M, EPS −$0.24
- Quarter ended Dec 31, 2023 (from the annual report): revenue $73.5M (up 55.0% year over year), net income $51.2M, EPS $0.97
- Quarter ended Sep 30, 2023: revenue $25.5M (up 1169.8% year over year), net income −$3.20M, EPS −$0.06
- Quarter ended Jun 30, 2023: revenue $2.72M (up 36.3% year over year), net income −$11.9M, EPS −$0.23
- Quarter ended Mar 31, 2023: revenue $2.07M (up 0.0% year over year), net income −$13.3M, EPS −$0.25
- Quarter ended Dec 31, 2022 (from the annual report): revenue $47.4M (up 1628.9% year over year), net income $26.8M, EPS $0.98
- Quarter ended Sep 30, 2022: revenue $2.01M (down 34.5% year over year), net income −$11.7M, EPS −$0.33
- Quarter ended Jun 30, 2022: revenue $1.99M (down 61.3% year over year), net income −$28.7M, EPS −$0.87
- Quarter ended Mar 31, 2022: revenue $2.07M (down 71.7% year over year), net income −$32.8M, EPS −$1.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue $2.74M, net income −$29.3M, EPS −$0.92
- Quarter ended Sep 30, 2021: revenue $3.06M, net income −$22.5M, EPS −$0.70
SPRO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$33.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.73M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$64.3M, share buybacks n/a
SPRO balance sheet
- Jun 30, 2026: cash $50.8M, total assets $52.8M, total liabilities $8.56M, shareholders' equity $44.2M
- Mar 31, 2026: cash $56.1M, total assets $59.0M, total liabilities $6.09M, shareholders' equity $52.9M
- Dec 31, 2025: cash $40.3M, total assets $68.9M, total liabilities $9.90M, shareholders' equity $59.0M
- Sep 30, 2025: cash $48.6M, total assets $54.2M, total liabilities $27.7M, shareholders' equity $26.5M
- Jun 30, 2025: cash $31.2M, total assets $62.1M, total liabilities $29.3M, shareholders' equity $32.8M
- Mar 31, 2025: cash $48.9M, total assets $77.7M, total liabilities $43.9M, shareholders' equity $33.8M
- Dec 31, 2024: cash $52.9M, total assets $111M, total liabilities $64.4M, shareholders' equity $46.1M
- Sep 30, 2024: cash $76.3M, total assets $135M, total liabilities $69.7M, shareholders' equity $65.5M
What is SPRO's revenue?
Spero Therapeutics Inc reported $47.0M of revenue over its last four quarters, through June 30, 2026.
Is SPRO profitable?
Yes. Spero Therapeutics Inc earned $7.38M over the last four quarters.
What is SPRO's EPS?
Diluted earnings per share over the last four quarters were $0.14; −$0.16 in the latest quarter.